News | August 08, 2007

Nuclear Oncology Medical Care First in Illinois to Install AccuBoost

August 8, 2007 - Nuclear Oncology Medical Care, DuPage Oncology Center in Winfield, IL, is the first cancer center in the state to install and use the AccuBoost System for image-guided treatment of breast cancer.

The AccuBoost’s first patient in Illinois is 76-year old Mrs. G. Miller who will receive the site-specific radiation treatment for breast cancer in sessions performed over eight days. The treatment is designed to deliver focused radiation to the lumpectomy cavity while minimizing the unintended exposure to the heart and lungs.

"This noninvasive, real-time image-guided treatment ensures better targeting of the lumpectomy cavity and makes it possible to see what you treat and treat what you see," said DuPage Oncology Center Radiation Oncologist, Dr. Dennis Galinsky.

Dr. Anantha Murthy, Associate Professor of Radiation Oncology at Rush Medical College and DuPage Oncology Center said, "When I saw this system at the recent American Brachytherapy Society meeting, I knew we needed to make it available to our patients. Targeting the boost dose has always been a challenge; this system solves the problem."

"Typically delivered prior to the main external beam breast irradiation, AccuBoost is presently used as a replacement for the electron boost that normally would follow the standard treatment," said DuPage Oncology Center's Chief of Medical Physics, Dr. Mohamed Hamadeh. "The breast is immobilized and imaged in a manner similar to mammography allowing a special applicator to be positioned, delivering the radiation with far better accuracy."

For more information:

Related Content

News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely...
Overlay Init